|
|
? |
SOUTH AFRICA: New anti-AIDS drug deal could short-change consumers
[This report does not necessarily reflect the views of the United Nations]
JOHANNESBURG, 26 April (PLUSNEWS) - The local pharmaceutical company, Aspen Pharmacare, will soon manufacture generic versions of two more patented anti-AIDS drugs and sell them in 95 developing countries.
According to the local Business Day newspaper, Aspen announced on Monday that under the terms of the deal, to be finalised in September, it would acquire the distribution rights in Africa for the antiretroviral (ARV) drugs Truvada and Viread, manufactured by US company Gilead.
Viread and Truvada are new-generation ARVs, increasingly prescribed in the US and Europe for strains of HIV that are resistant to other drugs because they have fewer side effects and are taken only once a day.
Aspen Pharmacare already produces generic copies of patented drugs made by GlaxoSmithKline, Boehringer-Ingelheim and Bristol-Meyers Squibb.
But AIDS activists raised concerns that under the deal, Aspen would simply take over part of Gilead's not-for-profit market, rather than becoming a competitor offering cheaper copies of the drugs.
[ENDS]
MORE NEWS BRIEFS
|
 |
|
? |
|
|
|
|
| Links |
Le portail d'informations générales de la Côte d’Ivoire
|
The Global Fund to fight AIDS, Tuberculosis & Malaria
|
AEGIS
|
Mothers and HIV/AIDS
|
PlusNews does not take responsibility for info in links supplied. |
|
|
|
|
|
[Back] [Home Page]
Click here to send any feedback,
comments or questions you have about PlusNews Website or if you prefer you can
send an Email to Webmaster
Copyright ? IRIN 2005
The material contained on www.PlusNews.org comes to you via IRIN, a UN humanitarian news and information service, but may not necessarily reflect
the views of the United Nations or its agencies.
All PlusNews material may be reposted or reprinted free-of-charge; refer to the IRIN copyright page for conditions of use. IRIN is a project of the UN
Office for the Coordination of Humanitarian Affairs.
|